Targeting a specific protein to improve treatment response in brain cancer
Therapeutic targeting of the SWI/SNF chromatin remodeler to regulate GBM chemosensitivity
This study is looking at ways to make treatments for glioblastoma, a tough type of brain cancer, work better by targeting a specific protein called BRG1, which helps the cancer resist treatment, so that patients can have a better chance at improved outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tennessee Health Sci Ctr NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project ID | NIH-10886053 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma (GBM), a highly aggressive brain cancer that often resists treatment. The study aims to identify and target specific molecular pathways that contribute to the cancer's resistance, particularly focusing on a protein called BRG1. By using a small molecule inhibitor, the research seeks to enhance the effectiveness of existing therapies, such as DNA alkylating agents, and improve the immune response against the tumor. Patients may benefit from a more effective treatment strategy that could lead to better outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma who are currently undergoing treatment or have treatment-resistant tumors.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with glioblastoma, potentially increasing their survival rates.
How similar studies have performed: Previous research has shown promise in targeting similar molecular pathways in other cancers, suggesting potential for success in this approach for glioblastoma.
Where this research is happening
Memphis, United States
- University of Tennessee Health Sci Ctr — Memphis, United States (Active)
Researchers
- Principal investigator: Pfeffer, Lawrence Marc — University of Tennessee Health Sci Ctr
- Study coordinator: Pfeffer, Lawrence Marc
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.